NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.
Private Equity Round in 2013
OptiScan Biomedical Corporation specializes in developing advanced glucose monitoring systems for use in intensive care units. The company is known for its OptiScanner 5000, an automated bedside platform that provides precise plasma-based glucose measurements using spectroscopy technology, eliminating the need for calibration. This system enables healthcare providers to monitor and respond to changes in glucose levels for critically ill patients effectively. Founded in 1994 and headquartered in Hayward, California, OptiScan Biomedical faced financial challenges, filing for Chapter 11 bankruptcy in June 2020 and subsequently converting to Chapter 7 bankruptcy in November 2020.
Private Equity Round in 2012
Pulmonx Corporation is a medical technology company that specializes in minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's core offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography images to aid in treatment planning. Pulmonx's solutions are intended for patients who remain symptomatic despite medical management and are either not candidates for or do not wish to pursue surgical options. The Zephyr Valve has received FDA pre-market approval and is supported by extensive clinical evidence demonstrating its benefits. Pulmonx serves a global market, with significant operations in the United States and various international regions, and has made a notable impact by treating thousands of patients with its innovative technology.
NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Sonoma Orthopedics specializes in the design and development of proprietary orthopedic implants aimed at addressing complex fractures. Utilizing the WaviBody technology platform, the company provides quick and minimally invasive surgical solutions tailored for active patients. Their focus is on fracture fixation devices that enable orthopedic surgeons to effectively repair challenging bone geometries. By offering operative treatments that facilitate faster recovery, Sonoma Orthopedics aims to help patients return to work and their daily activities sooner.
Game Ready is a medical device maker focused on treating post-surgical orthopedic sports injuries. The company operates primarily through its flagship product GameReady. The GameReady device essentially provides ice cold water and pressure to injured joints/body parts.
Pulmonx Corporation is a medical technology company that specializes in minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's core offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography images to aid in treatment planning. Pulmonx's solutions are intended for patients who remain symptomatic despite medical management and are either not candidates for or do not wish to pursue surgical options. The Zephyr Valve has received FDA pre-market approval and is supported by extensive clinical evidence demonstrating its benefits. Pulmonx serves a global market, with significant operations in the United States and various international regions, and has made a notable impact by treating thousands of patients with its innovative technology.
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
Sleep Solutions (SSI) is a privately held diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions® offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary sound analysis technology, their NovaSom® QSG® home-diagnostic system is delivered directly to the patient.
BeneChill, Inc., a medical device company, develops non-invasive cooling technologies in the United States and Europe. The company develops non-invasive cooling technologies to improve patient outcomes after acute ischemic events, such as cardiac arrest, stroke, and traumatic brain injury. Its RhinoChill System focuses on reducing patient temperature. The company was founded in 2004 and is headquartered in San Diego, California.
SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.
NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
Pavad Medical
Series C in 2007
PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.
Game Ready is a medical device maker focused on treating post-surgical orthopedic sports injuries. The company operates primarily through its flagship product GameReady. The GameReady device essentially provides ice cold water and pressure to injured joints/body parts.
BeneChill, Inc., a medical device company, develops non-invasive cooling technologies in the United States and Europe. The company develops non-invasive cooling technologies to improve patient outcomes after acute ischemic events, such as cardiac arrest, stroke, and traumatic brain injury. Its RhinoChill System focuses on reducing patient temperature. The company was founded in 2004 and is headquartered in San Diego, California.
Intact Medical Corporation designs, develops, and markets minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. Intact Medical Corporation was formerly known as Neothermia Corporation and changed its name to Intact Medical Corporation in November 2005. It is driven by its mission to alleviate pain, restore health, and extend life. The company was founded in 1998 and is based in Framingham, Massachusetts.
Sonoma Orthopedics specializes in the design and development of proprietary orthopedic implants aimed at addressing complex fractures. Utilizing the WaviBody technology platform, the company provides quick and minimally invasive surgical solutions tailored for active patients. Their focus is on fracture fixation devices that enable orthopedic surgeons to effectively repair challenging bone geometries. By offering operative treatments that facilitate faster recovery, Sonoma Orthopedics aims to help patients return to work and their daily activities sooner.
Pulmonx Corporation is a medical technology company that specializes in minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's core offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography images to aid in treatment planning. Pulmonx's solutions are intended for patients who remain symptomatic despite medical management and are either not candidates for or do not wish to pursue surgical options. The Zephyr Valve has received FDA pre-market approval and is supported by extensive clinical evidence demonstrating its benefits. Pulmonx serves a global market, with significant operations in the United States and various international regions, and has made a notable impact by treating thousands of patients with its innovative technology.
EKOS Corporation is a pioneering company focused on the clinical application of ultrasound accelerated thrombolysis for the treatment of vascular thrombosis. Since its inception in 2005, EKOS has developed innovative technologies, including the EkoSonic Endovascular System, which utilizes microsonic technologies for the controlled and selective infusion of fluids specified by physicians. This system is employed by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions worldwide, enabling faster, safer, and more complete dissolution of thrombus, thereby enhancing patient outcomes in vascular care.
Asthmatx, Inc. is a medical device company based in Mountain View, California, that specializes in the development and commercialization of therapeutic treatments for asthma. Founded in 2003, the company has created a technology that delivers controlled thermal energy to the airways of adult patients, aimed at reducing the mass of airway smooth muscle through a procedure known as Bronchial Thermoplasty. Asthmatx offers the Alair System, an interventional medical device designed for bronchoscopic treatment of patients suffering from moderate to severe asthma. As of October 2010, Asthmatx operates as a wholly-owned subsidiary of Boston Scientific.
Pavad Medical
Series B in 2005
PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.
OptiScan Biomedical Corporation specializes in developing advanced glucose monitoring systems for use in intensive care units. The company is known for its OptiScanner 5000, an automated bedside platform that provides precise plasma-based glucose measurements using spectroscopy technology, eliminating the need for calibration. This system enables healthcare providers to monitor and respond to changes in glucose levels for critically ill patients effectively. Founded in 1994 and headquartered in Hayward, California, OptiScan Biomedical faced financial challenges, filing for Chapter 11 bankruptcy in June 2020 and subsequently converting to Chapter 7 bankruptcy in November 2020.
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
Alteer
Venture Round in 2005
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.
Intact Medical Corporation designs, develops, and markets minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. Intact Medical Corporation was formerly known as Neothermia Corporation and changed its name to Intact Medical Corporation in November 2005. It is driven by its mission to alleviate pain, restore health, and extend life. The company was founded in 1998 and is based in Framingham, Massachusetts.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
EKOS Corporation is a pioneering company focused on the clinical application of ultrasound accelerated thrombolysis for the treatment of vascular thrombosis. Since its inception in 2005, EKOS has developed innovative technologies, including the EkoSonic Endovascular System, which utilizes microsonic technologies for the controlled and selective infusion of fluids specified by physicians. This system is employed by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions worldwide, enabling faster, safer, and more complete dissolution of thrombus, thereby enhancing patient outcomes in vascular care.
Aesthera is a California-based company dedicated to transforming the realm of high technology aesthetics through innovative therapies. Founded by a skilled team with extensive experience in laser research and development, Aesthera has established strong connections within the medical community and has successfully penetrated global markets for medical devices. The company specializes in light-based aesthetic treatments, notably through its breakthrough Photopneumatic Therapy (PPx), which offers a range of firsts for both physicians and patients. This includes painless treatments that do not require pre-treatments, the ability to treat legs and backs in under twenty minutes, and hygienic procedures that are significantly safer and more effective than traditional methods. Aesthera's advancements aim to enhance the quality of aesthetic care while prioritizing patient comfort and safety.
Aesthera is a California-based company dedicated to transforming the realm of high technology aesthetics through innovative therapies. Founded by a skilled team with extensive experience in laser research and development, Aesthera has established strong connections within the medical community and has successfully penetrated global markets for medical devices. The company specializes in light-based aesthetic treatments, notably through its breakthrough Photopneumatic Therapy (PPx), which offers a range of firsts for both physicians and patients. This includes painless treatments that do not require pre-treatments, the ability to treat legs and backs in under twenty minutes, and hygienic procedures that are significantly safer and more effective than traditional methods. Aesthera's advancements aim to enhance the quality of aesthetic care while prioritizing patient comfort and safety.
Pulmonx Corporation is a medical technology company that specializes in minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's core offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography images to aid in treatment planning. Pulmonx's solutions are intended for patients who remain symptomatic despite medical management and are either not candidates for or do not wish to pursue surgical options. The Zephyr Valve has received FDA pre-market approval and is supported by extensive clinical evidence demonstrating its benefits. Pulmonx serves a global market, with significant operations in the United States and various international regions, and has made a notable impact by treating thousands of patients with its innovative technology.
Sleep Solutions (SSI) is a privately held diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions® offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary sound analysis technology, their NovaSom® QSG® home-diagnostic system is delivered directly to the patient.
Intact Medical Corporation designs, develops, and markets minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. Intact Medical Corporation was formerly known as Neothermia Corporation and changed its name to Intact Medical Corporation in November 2005. It is driven by its mission to alleviate pain, restore health, and extend life. The company was founded in 1998 and is based in Framingham, Massachusetts.
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.
Sleep Solutions (SSI) is a privately held diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions® offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary sound analysis technology, their NovaSom® QSG® home-diagnostic system is delivered directly to the patient.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
Sleep Solutions (SSI) is a privately held diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions® offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary sound analysis technology, their NovaSom® QSG® home-diagnostic system is delivered directly to the patient.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.